BioNTech's Credibility Test: A Broker Downgrade, a Halted Colon Cancer Trial, and a Factory Decision Looming

BMO cut BioNTech to Market Perform and its target to $105, as the biotech trimmed 2026 revenue guidance and a Phase 2 cancer trial halted.

The last major bull on BioNTech has blinked. On Tuesday, BMO Capital Markets stripped the Mainz-based biotech of its Outperform rating, moving to Market Perform and cutting its price target from $128 to $105. The reasoning was blunt: softer demand for the COVID-19 vaccine, ongoing inventory destocking in Germany, and a view that the company's core oncology programs are unlikely to be meaningfully de-risked before 2028.

That call landed alongside a guidance cut. BioNTech trimmed its full-year revenue outlook to EUR 1.6 billion to EUR 1.9 billion, down from the EUR 2.0 billion to EUR 2.3 billion previously on the table. When one of the few remaining vocal supporters steps back, the read-through is less about a temporary air pocket and more about a structural problem in the core business.

A Flagship Oncology Program Stops Early

The timing could hardly be worse. Just a week earlier, BioNTech and Roche's Genentech jointly halted a Phase 2 study of their colorectal cancer candidate Autogene Cevumeran after an independent monitoring committee concluded that continuing would yield little in the way of meaningful efficacy data. The committee also flagged a numerical imbalance in overall survival between the study arms. US-listed shares fell 7.5% on that news.

It is not a blanket setback for the program. The separate Phase 2 IMcode003 trial testing the same agent in pancreatic cancer is unaffected and continues to enroll. Writing off the entire oncology pipeline would go too far — but the benefit of the doubt investors had been extending is likely to shrink.

Mixed Signals From the Shareholder Register

Ownership moves add to the unease. CEO Ugur Sahin sold roughly 31,500 shares in a transaction dated September 4, executed under a pre-arranged Rule 10b5-1 trading plan. Such plans are legally clean and not automatically a red flag, though stacked against the other headlines they do little to steady nerves.

Institutions are adjusting too. French asset manager Carmignac Gestion cut its BioNTech stake by 29.1% in the second quarter, offloading 32,836 shares, according to a filing. That left just under 80,000 shares in the portfolio. One fund's sale is not a trend on its own, but it fits the picture of a stock with more doubters than champions right now.

Not Everyone Has Thrown in the Towel

The bear case is not unanimous. Goldman Sachs trimmed its price target on September 4 from $128 to $127 while keeping a Buy rating. The token adjustment suggests the bank is pricing in operational headwinds without abandoning its view that upside remains.

There was also a regulatory win worth noting: the FDA approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026/27 season, tailored to the currently dominant XFG variant. That secures market access for the seasonal shot, though it has yet to offset the structural decline in demand.

The Next Catalyst: A Factory Decision by End-September

Attention is now shifting to a date already on the calendar. By the end of September, BioNTech intends to decide the fate of three manufacturing sites in Germany and Singapore — Idar-Oberstein, Marburg, and Singapore. The backdrop is the shrinking COVID-19 vaccine market, which is forcing a fundamental rethink of production capacity. The outcome should reveal how seriously management views the demand slump and what cost base investors will need to factor into next year's numbers.

Where the Stock Stands

The shares closed most recently at EUR 83.05 after a 1.7% decline the prior day, with the stock at EUR 82.65 at the time of writing. Over the past seven trading sessions, the equity has shed 6.6%, and on a weekly basis it is down 7.0%, even as it holds a 3.2% gain over 30 days. The 52-week high of EUR 105.80 — set in January — now sits 22% above the current price, a gap that captures how much confidence has drained out over recent months.

For now, the risk factors carry more weight: a slashed revenue forecast, a high-profile oncology trial termination, and selling by both the CEO and institutional holders. That does not mean the underlying business has evaporated — the ongoing pancreatic cancer study shows the pipeline is not entirely fallow. But the story BioNTech needs to justify its valuation has gotten thinner, and the market is reflecting that skepticism for good reason.